AXA1125

AXA1125
Combination of
Leucine	Amino acid
Isoleucine	Amino acid
Valine	Amino acid
Arginine	Amino acid
Glutamine	Amino acid
N-Acetylcysteine	Amino acid derivative
Clinical data
Other names	LIVRQNac
Chemical and physical data
3D model (JSmol)	Interactive image;
	SMILES N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N(C(=O)C)[C@@]([H])(CS)C(=O)O;

AXA1125 is an experimental drug developed by Axcella Health that "increased β-oxidation and improved bioenergetics in preclinical models". It was studied as a treatment for non-alcoholic fatty liver disease and long COVID.^[1]^[2]^[3]^[4]

AXA1125 is a fixed composition comprising five amino acids (leucine, isoleucine, valine, arginine, and glutamine) and an amino acid derivative (N-acetylcysteine).^[5]

References

^ Harrison, Stephen A.; Baum, Seth J.; Gunn, Nadege T.; Younes, Ziad H.; Kohli, Anita; Patil, Rashmee; Koziel, Margaret J.; Chera, Harinder; Zhao, Jeff; Chakravarthy, Manu V. (December 2021). "Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease". The American Journal of Gastroenterology. 116 (12): 2399–2409. doi:10.14309/ajg.0000000000001375. ISSN 0002-9270. PMC 8631161. PMID 34382947.
^ Finnigan, Lucy E.M.; Cassar, Mark Philip; Koziel, Margaret James; Pradines, Joel; Lamlum, Hanan; Azer, Karim; Kirby, Dan; Montgomery, Hugh; Neubauer, Stefan; Valkovič, Ladislav; Raman, Betty (May 2023). "Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study". eClinicalMedicine. 59: 101946. doi:10.1016/j.eclinm.2023.101946. PMC 10102537. PMID 37223439.
^ Park, Brian. "Orally Active Amino Acid Mixture Fast Tracked for NASH With Liver Fibrosis." Medical Bag, 16 Feb. 2022, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A693790920/HRCA?u=anon~8aede0d3&sid=googleScholar&xid=1e146086. Accessed 3 Dec. 2023.
^ "Axcella antes up in key liver diseases with EMM (endogenous metabolic modulator) compositions". Retrieved 3 December 2023.
^ Daou, Nadine; Viader, Andreu; Cokol, Murat; Nitzel, Arianna; Chakravarthy, Manu V.; Afeyan, Raffi; Tramontin, Tony; Marukian, Svetlana; Hamill, Michael J. (2021). "A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models". Scientific Reports. 11 (1): 11861. Bibcode:2021NatSR..1111861D. doi:10.1038/s41598-021-88913-1. PMC 8178416. PMID 34088912.

[1] Harrison, Stephen A.; Baum, Seth J.; Gunn, Nadege T.; Younes, Ziad H.; Kohli, Anita; Patil, Rashmee; Koziel, Margaret J.; Chera, Harinder; Zhao, Jeff; Chakravarthy, Manu V. (December 2021). "Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease". The American Journal of Gastroenterology. 116 (12): 2399–2409. doi:10.14309/ajg.0000000000001375. ISSN 0002-9270. PMC 8631161. PMID 34382947.

[2] Finnigan, Lucy E.M.; Cassar, Mark Philip; Koziel, Margaret James; Pradines, Joel; Lamlum, Hanan; Azer, Karim; Kirby, Dan; Montgomery, Hugh; Neubauer, Stefan; Valkovič, Ladislav; Raman, Betty (May 2023). "Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study". eClinicalMedicine. 59: 101946. doi:10.1016/j.eclinm.2023.101946. PMC 10102537. PMID 37223439.

[3] Park, Brian. "Orally Active Amino Acid Mixture Fast Tracked for NASH With Liver Fibrosis." Medical Bag, 16 Feb. 2022, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A693790920/HRCA?u=anon~8aede0d3&sid=googleScholar&xid=1e146086. Accessed 3 Dec. 2023.

[4] "Axcella antes up in key liver diseases with EMM (endogenous metabolic modulator) compositions". Retrieved 3 December 2023.

[5] Daou, Nadine; Viader, Andreu; Cokol, Murat; Nitzel, Arianna; Chakravarthy, Manu V.; Afeyan, Raffi; Tramontin, Tony; Marukian, Svetlana; Hamill, Michael J. (2021). "A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models". Scientific Reports. 11 (1): 11861. Bibcode:2021NatSR..1111861D. doi:10.1038/s41598-021-88913-1. PMC 8178416. PMID 34088912.

[1]

[2]

[3]

[4]

[5]